Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines

European Journal of Cancer

Volumn 91, Issue , 2018, Pages 68-75

  Pedersen, Kine ^a   Burger, Emily A ^a,b   Nygård, Mari ^c   Kristiansen, Ivar S ^a   Kim, Jane J ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

Cervical cancer; Cost effectiveness analysis; Human papillomavirus; Mass screening; Mathematical model

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER SCREENING; CHILD; COLPOSCOPY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; FREQUENCY; HUMAN; PAPILLOMAVIRUS INFECTION; PILOT STUDY; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; SCREENING TEST; SIMULATION; TUMOR INVASION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VACCINATION; YOUNG ADULT; AGE; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMIC MODEL; ECONOMICS; HEALTH CARE COST; NORWAY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROTECTION; QUALITY OF LIFE; RISK FACTOR; STANDARDS; TIME FACTOR; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGE FACTORS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; NORWAY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROTECTIVE FACTORS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 85040359620     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.12.018     Document Type: Article

References (26)

1. Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. 2013, International Agency for Research on Cancer, Lyon, France Accessed at http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp on December 4, 2017.
2. Guan, P., Howell-Jones, R., Li, N., Bruni, L., de Sanjose, S., Franceschi, S., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 131:10 (2012), 2349–2359.
3. Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 372:8 (2015), 711–723.
4. Paavonen, J., Naud, P., Salmeron, J., Wheeler, C.M., Chow, S.N., Apter, D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:9686 (2009), 301–314.
5. Naud, P.S., Roteli-Martins, C.M., De Carvalho, N.S., Teixeira, J.C., de Borba, P.C., Sanchez, N., et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccines Immunother 10:8 (2014), 2147–2162.
6. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356:19 (2007), 1915–1927.
7. Castellsague, X., Munoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. BJC 105:1 (2011), 28–37.
8. Norwegian Institute of Public Health. HPV-vaccination: changes in the childhood immunization program from the fall of 2017. Last updated May 4, 2017. Accessed at https://fhi.no/sv/vaksine/barnevaksinasjonsprogrammet/endring-for-hpv-vaksine-i-barnevaksinasjonsprogrammet/ on June 2, 2017.
9. Kim, J.J., Burger, E.A., Sy, S., Campos, N.G., Optimal cervical cancer screening in women vaccinated against human papillomavirus. J Natl Canc Inst, 109(2), 2017.
10. Simms, K.T., Smith, M.A., Lew, J.B., Kitchener, H.C., Castle, P.E., Canfell, K., Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. Int J Cancer 139:12 (2016), 2771–2780.
11. Burger, E.A., Ortendahl, J.D., Sy, S., Kristiansen, I.S., Kim, J.J., Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Canc 106:9 (2012), 1571–1578.
12. Naber, S.K., Matthijsse, S.M., Rozemeijer, K., Penning, C., de Kok, I.M., van Ballegooijen, M., Cervical cancer screening in partly HPV vaccinated cohorts - a cost-effectiveness analysis. PLos One, 11(1), 2016, e0145548.
13. Goldhaber-Fiebert, J.D., Stout, N.K., Salomon, J.A., Kuntz, K.M., Goldie, S.J., Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Canc Inst 100:5 (2008), 308–320.
14. Campos, N.G., Burger, E.A., Sy, S., Sharma, M., Schiffman, M., Rodriguez, A.C., et al. An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol 180:5 (2014), 545–555.
15. Pedersen, K., Burger, E.A., Sy, S., Kristiansen, I.S., Kim, J.J., Cost-effective management of women with minor cervical lesions: revisiting the application of HPV DNA testing. Gynecol Oncol 143:2 (2016), 326–333.
16. Norwegian Technical Appendix, Harvard cervical cancer natural history model calibration and costing approach for Norway. 2017 Accessed at http://www.med.uio.no/helsam/english/research/projects/preventive-strategies-hpv/17-harvardmodel-norway-technicalappendix.pdf on May 10, 2017.
17. Nygard, M., Andreassen, T., Berland, J., Hagen, B., Hagmar, B., Iversen, O.-E., et al. HPV testing in primary screening for cervical cancer. Controlled implementation and evaluation of improved health service. 2013, The Norwegian Directorate of Health, Oslo.
18. The Central Bank of Norway, Average exchange rates 2014. 2014 Available at: http://www.norgesbank.no/Statistikk/Valutakurser/valuta/EUR/ Accessed: January 19, 2016.
19. Norwegian Directorate of Health. Economic evaluation of health interventions - A guide, 2012 Accessed at: http://helsedirektoratet.no/publikasjoner/okonomiskevaluering-av-helsetiltak–en-veileder/Publikasjoner/IS-1985.pdf on September 15, 2014.
20. Norwegian Medicines Agency, Medicine database: cervarix. 2017 Accessed at https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=12f12e28-0e1a-49cc-b409-3f5015ed2c2a&searchquery=cervarix&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0 on May 5, 2017.
21. Norwegian Medicines Agency, Medicine database: Gardasil 9. 2017 Accessed at https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=30aecd9c-c6be-4494-850d-e9f9d7bc8cee&searchquery=gardasil%209&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=0 on May 5, 2017.
22. Norwegian Directorate of Health, Health effects of socio-economic analyses. 2007, Norwegian Directorate of Health, Oslo.
23. Malagon, T., Drolet, M., Boily, M.C., Franco, E.L., Jit, M., Brisson, J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12:10 (2012), 781–789.
24. Cancer Registry of Norway, Annual report of the Norwegian cervical cancer screening program., 2015, Cancer Registry of Norway, Oslo 2013-14 Accessed at. https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/livmorhalskreft/arsrapport/livmorhals_2015.pdf, on October 16, 2015.
25. Landy, R., Windridge, P., Gillman, M.S., Sasieni, P.D., What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer 142:4 (2017), 709–718.
26. World Health Organization, Evidence based recommendations on human papilloma virus (HPV) vaccines schedules. Background paper for SAGE discussions, 2014 Accessed at http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf on May 6, 2017.